Search This Blog

Wednesday, May 13, 2026

BeOne accelerated approval for BEQALZI, first BCL2 inhibitor for relapsed, refractory mantle cell lymphoma

 

BeOne Medicines gets U.S. FDA accelerated approval for BEQALZI, first BCL2 inhibitor for relapsed or refractory mantle cell lymphoma after BTK therapy

  • BEQALZI (sonrotoclax) is approved for adult mantle cell lymphoma patients who have previously been treated with a BTK inhibitor.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)